This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Supplemental material
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Google Scholar
Right arrow Articles by Yu, X.
Right arrow Articles by Uprichard, S. L.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Yu, X.
Right arrow Articles by Uprichard, S. L.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, October 2009, p. 4311-4319, Vol. 53, No. 10
0066-4804/09/$08.00+0     doi:10.1128/AAC.00495-09
Copyright © 2009, American Society for Microbiology. All Rights Reserved.

Development of a Cell-Based Hepatitis C Virus Infection Fluorescent Resonance Energy Transfer Assay for High-Throughput Antiviral Compound Screening{triangledown} ,{dagger}

Xuemei Yu,1 Bruno Sainz Jr.,1 and Susan L. Uprichard1,2*

Department of Medicine,1 Department of Microbiology and Immunology, the University of Illinois at Chicago, Chicago, Illinois 606122

Received 15 April 2009/ Returned for modification 5 June 2009/ Accepted 10 July 2009

A major obstacle in the treatment of chronic hepatitis C virus (HCV) infection has been the lack of effective, well-tolerated therapeutics. Notably, the recent development of the HCV cell culture infection system now allows not only for the study of the entire viral life cycle, but also for the screening of inhibitors against all aspects of HCV infection. However, in order to screen libraries of potential antiviral compounds, it is necessary to develop a highly reproducible, accurate assay for HCV infection adaptable for high-throughput screening (HTS) automation. Using an internally quenched 5-FAM/QXL 520 fluorescence resonance energy transfer (FRET) substrate containing the HCV NS3 peptide cleavage sequence, we report the development of a simple, mix-and-measure, homogenous, cell-based HCV infection assay amendable for HTS. This assay makes use of synchronized, nondividing human hepatoma-derived Huh7 cells, which support more-reproducible long-term HCV infection and can be readily scaled down to a 96-well-plate format. We demonstrate that this stable cell culture method eliminates common problems associated with standard cell-based HTS, such as cell culture variability, poor reproducibility, and low signal intensity. Importantly, this HCV FRET assay not only can identify inhibitors that act throughout the viral life cycle as effectively as more-standard HCV assays, such as real-time quantitative PCR and Western blot analysis, but also exhibits a high degree of accuracy with limited signal variation (i.e., Z' ≥ 0.6), providing the basis for a robust HTS campaign for screening compound libraries and identifying novel HCV antivirals.


* Corresponding author. Mailing address: Department of Medicine, Section of Hepatology, the University of Illinois at Chicago, 840 S. Wood Street M/C 787, Chicago, IL 60612. Phone: (312) 355-5120. Fax: (312) 413-0342. E-mail: sluprich{at}uic.edu

{triangledown} Published ahead of print on 20 July 2009.

{dagger} Supplemental material for this article may be found at http://aac.asm.org/.


Antimicrobial Agents and Chemotherapy, October 2009, p. 4311-4319, Vol. 53, No. 10
0066-4804/09/$08.00+0     doi:10.1128/AAC.00495-09
Copyright © 2009, American Society for Microbiology. All Rights Reserved.




This article has been cited by other articles:

  • Pan, K.-L., Lee, J.-C., Sung, H.-W., Chang, T.-Y., Hsu, J. T.-A. (2009). Development of NS3/4A Protease-Based Reporter Assay Suitable for Efficiently Assessing Hepatitis C Virus Infection. Antimicrob. Agents Chemother. 53: 4825-4834 [Abstract] [Full Text]